Merck Serono bags MS licence option
Enlarge image


Merck Serono bags MS licence option

06.02.2013 - Merck Serono has secured an exclusive licence option for Opexa Therapeutics’ autologous T cell-based Multiple Sclerosis therapy imilecleucel-T.

Opexa’s Tcelna (imilecleucel-T) therapy currently is tested in a Phase IIb study on patients with Secondary Progressive MS (SPMS), which is less common than relapsing forms of MS that are targeted by Merck’s blockbuster Rebif® (interferon beta-1a)  In case of market entry and successful commercialisation, the US firm could gain US$225m in total from the option and license agreement.

Under the terms of the contract, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) programme as a treatment of MS. The option may be exercised prior to, or upon completion of, Opexa’s proof-of-concept trial. If Merck Serono opts for the programme, Opexa is eligible for $25m or $15m upfront depending on fulfilment of certain undisclosed conditions. The Germans, in return, would receive worldwide development and commercial rights in MS, excluding Japan. When exercising the option, Merck Serono would have to pay all clinical development, as well as the cost for regulatory authorisation and marketing of the MS programme. Milestone payments to Opexa could sum up to $195m plus a tiered royalty rate from the high single digits to the mid-teens based on net sales.

Under the agreement, Opexa will have an option right to co-fund development, under which the company would participate in economic support for future clinical development of the programme in exchange for additional royalty consideration. In addition to retaining all rights outside of MS as well as retaining the ability to commercialise imilecleucel-T in Japan, Opexa also retains certain manufacturing rights related to the programme. 

Tcelna (imilecleucel-T) is an autologous T cell therapy. After collection of peripheral blood mononuclear cells, myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) are expanded, irradiated and given back to the patient subcutaneously to trigger a therapeutic immune response.



12.10.2015 Aberdeen University spinout TauRx has picked up US$135m from a VC financing round. The biopharma company plans to bring its dementia hopeful through Phase III trials.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • PHARMING (NL)0.32 EUR10.34%
  • PLETHORA (UK)3.12 GBP8.33%


  • THERAMETRICS (CH)0.03 CHF-25.00%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • OREXO (S)65.00 SEK44.4%
  • THROMBOGENICS (B)3.98 EUR25.2%


  • THERAMETRICS (CH)0.03 CHF-50.0%
  • GALAPAGOS (B)38.68 EUR-25.8%


  • KARO BIO (S)41.90 SEK5009.8%
  • CHRONTECH PHARMA (S)0.34 SEK385.7%
  • GALAPAGOS (B)38.68 EUR253.2%


  • NEOVACS (F)0.75 EUR-76.8%
  • BIOTEST (D)19.54 EUR-72.8%

No liability assumed, Date: 13.10.2015